The post-pandemic recovery has been uneven for the pharma industry, with stressed healthcare systems leading to launches struggling. This will continue to be the case for some time, says IQVIA’s Helena Bayley, but despite the challenges, new therapies are set to drive significant growth.
At CDMO Live on June 13th, Helena Bayley, Thought Leader from IQVIA will present a data-driven analysis of how the BioPharma industry has evolved since the pandemic, and the emerging therapies that are ready to capture the market. The following is an exclusive preview of her talk.
Struggling healthcare systems
The COVID-19 pandemic led to a significant slowdown as constrained healthcare systems around the world struggled. This negatively impacted the success of innovative launches, with volume improvements largely driven by generic drugs.
Growth is returning
However, in 2023 the global market grew faster than any other post-pandemic year (exclusive of COVID-19 Vx and Tx)
New brands are back in the driving seat
Spending in Europe is expected to increase by $70 Billion USD through 2028, with new brands forecast to drive a significant proportion.
Don’t miss Competing in Biopharma: Cutting-edge trends for CDMOs, with Helena Bayley at CDMO Live.
Join the full talk for a comprehensive discussion on key trends and growth hotspots, a top line summary of the obesity market, and how clinical trial activity is shaping the pipeline of tomorrow’s medicines, including:
- The major therapy areas driving growth
- How medicine use is growing at different rates by region
- Top 4 disease areas accounting for 80% of clinical trials starts
- Forecasting the growth of obesity drugs
Register here for your free ticket
Stay ahead of trends and best practices
